Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 107

1.

Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study.

Sandler KA, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Song DY, Klein EA, Stephenson AJ, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco SC, Deville C, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR, Kishan AU.

Int J Radiat Oncol Biol Phys. 2018 Jul 15;101(4):883-888. doi: 10.1016/j.ijrobp.2018.03.060. Epub 2018 Apr 5.

PMID:
29976500
2.
3.

Factors influencing long-term urinary symptoms after prostate brachytherapy.

Stone NN, Winoker JS, Kaplan SA, Stock RG.

BJU Int. 2018 Nov;122(5):831-836. doi: 10.1111/bju.14365. Epub 2018 May 31.

PMID:
29726091
4.

Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer.

Kishan AU, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Sandler KA, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Stephenson AJ, Klein EA, Song DY, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco S, Deville C, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR.

JAMA. 2018 Mar 6;319(9):896-905. doi: 10.1001/jama.2018.0587.

5.

Low-dose-rate brachytherapy for prostate cancer: outcomes at >10 years of follow-up.

Lazarev S, Thompson MR, Stone NN, Stock RG.

BJU Int. 2018 May;121(5):781-790. doi: 10.1111/bju.14122. Epub 2018 Jan 30.

PMID:
29319928
6.

Outcomes and toxicities in patients with intermediate-risk prostate cancer treated with brachytherapy alone or brachytherapy and supplemental external beam radiation therapy.

Schlussel Markovic E, Buckstein M, Stone NN, Stock RG.

BJU Int. 2018 May;121(5):774-780. doi: 10.1111/bju.14128. Epub 2018 Feb 16.

PMID:
29319919
7.

American Brachytherapy Society Task Group Report: Combination of brachytherapy and external beam radiation for high-risk prostate cancer.

Spratt DE, Soni PD, McLaughlin PW, Merrick GS, Stock RG, Blasko JC, Zelefsky MJ.

Brachytherapy. 2017 Jan - Feb;16(1):1-12. doi: 10.1016/j.brachy.2016.09.006. Epub 2016 Oct 19. Review.

PMID:
27771243
8.

Urinary Incontinence Following Prostate Brachytherapy.

Leapman MS, Stone NN, Mock S, Stock RG, Hall SJ.

Urology. 2016 Sep;95:151-7. doi: 10.1016/j.urology.2016.05.021. Epub 2016 May 19.

PMID:
27210574
9.

Diagnosis and management of local recurrence after low-dose-rate brachytherapy.

Stone NN, Unger P, Crawford ED, Stock RG.

Brachytherapy. 2015 Mar-Apr;14(2):124-30. doi: 10.1016/j.brachy.2014.08.046. Epub 2014 Sep 16. Review.

PMID:
25239396
10.

Findings at cystoscopy performed for cause after prostate brachytherapy.

Leapman MS, Stock RG, Stone NN, Hall SJ.

Urology. 2014 Jun;83(6):1350-5. doi: 10.1016/j.urology.2014.01.031. Epub 2014 Apr 3.

PMID:
24704325
11.

15-year cause specific and all-cause survival following brachytherapy for prostate cancer: negative impact of long-term hormonal therapy.

Stone NN, Stock RG.

J Urol. 2014 Sep;192(3):754-9. doi: 10.1016/j.juro.2014.03.094. Epub 2014 Mar 31.

PMID:
24698961
12.

Does dose matter? Editorial comments to Morris et al. Whole prostate D90 and V100: a dose-response analysis of 2000 consecutive (125)I monotherapy cases.

Stone NN, Stock RG.

Brachytherapy. 2014 Jan-Feb;13(1):42-3. doi: 10.1016/j.brachy.2013.11.009. Epub 2013 Dec 15. No abstract available.

PMID:
24345527
13.

Association of early PSA failure time with increased distant metastasis and decreased survival in prostate brachytherapy patients.

Ko EC, Liu JT, Stone NN, Stock RG.

Radiother Oncol. 2014 Feb;110(2):261-7. doi: 10.1016/j.radonc.2013.11.003. Epub 2013 Nov 30.

PMID:
24299969
14.

Predictive factors and management of rectal bleeding side effects following prostate cancer brachytherapy.

Price JG, Stone NN, Stock RG.

Int J Radiat Oncol Biol Phys. 2013 Aug 1;86(5):842-7. doi: 10.1016/j.ijrobp.2013.04.033.

PMID:
23845840
15.

The relative importance of hormonal therapy and biological effective dose in optimizing prostate brachytherapy treatment outcomes.

Stock RG, Buckstein M, Liu JT, Stone NN.

BJU Int. 2013 Jul;112(2):E44-50. doi: 10.1111/bju.12166. Epub 2013 Jun 14.

16.

Genome-wide association study identifies a region on chromosome 11q14.3 associated with late rectal bleeding following radiation therapy for prostate cancer.

Kerns SL, Stock RG, Stone NN, Blacksburg SR, Rath L, Vega A, Fachal L, Gómez-Caamaño A, De Ruysscher D, Lammering G, Parliament M, Blackshaw M, Sia M, Cesaretti J, Terk M, Hixson R, Rosenstein BS, Ostrer H.

Radiother Oncol. 2013 Jun;107(3):372-6. doi: 10.1016/j.radonc.2013.05.001. Epub 2013 May 26.

17.

Risk of urinary incontinence following post-brachytherapy transurethral resection of the prostate and correlation with clinical and treatment parameters.

Mock S, Leapman M, Stock RG, Hall SJ, Stone NN.

J Urol. 2013 Nov;190(5):1805-10. doi: 10.1016/j.juro.2013.05.010. Epub 2013 May 10.

PMID:
23669568
18.

Prostate brachytherapy in men with gland volume of 100cc or greater: Technique, cancer control, and morbidity.

Stone NN, Stock RG.

Brachytherapy. 2013 May-Jun;12(3):217-21. doi: 10.1016/j.brachy.2012.10.002. Epub 2013 Feb 4.

PMID:
23384439
19.

A 2-stage genome-wide association study to identify single nucleotide polymorphisms associated with development of urinary symptoms after radiotherapy for prostate cancer.

Kerns SL, Stone NN, Stock RG, Rath L, Ostrer H, Rosenstein BS.

J Urol. 2013 Jul;190(1):102-8. doi: 10.1016/j.juro.2013.01.096. Epub 2013 Feb 1.

PMID:
23376709
20.

Long-term outcomes and toxicity in patients treated with brachytherapy for prostate adenocarcinoma younger than 60 years of age at treatment with minimum 10 years of follow-up.

Buckstein M, Carpenter TJ, Stone NN, Stock RG.

Urology. 2013 Feb;81(2):364-8. doi: 10.1016/j.urology.2012.08.112.

PMID:
23374803

Supplemental Content

Loading ...
Support Center